2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

European Journal of Cancer

Volumn 47, Issue 1, 2011, Pages 8-32

  Aapro, M S ^a   Bohlius, J ^b   Cameron, D A ^c   Lago, Lissandra Dal ^d   Donnelly, J Peter ^e   Kearney, N ^f   Lyman, G H ^g   Pettengell, R ^h   Tjan Heijnen, V C ⁱ   Walewski, J ^j   Weber, Damien C ^k   Zielinski, C ^l  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d EORTC DATA CENTER   (Belgium)

^e RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

^g DUKE CANCER INSTITUTE   (United States)

^h ST GEORGE S HOSPITAL   (United Kingdom)

ⁱ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^j INSTITUTE OF ONCOLOGY   (Poland)

^k GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^l MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

Antineoplastic agents; Filgrastim; Granulocyte colony stimulating factor; Guideline; Lenograstim; Neoplasms; Neutropenia; Pegfilgrastim

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOXANTRONE; NAVELBINE; PACLITAXEL; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TIRAPAZAMINE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; FEBRILE NEUTROPENIA; GERM CELL TUMOR; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; INCIDENCE; INFECTION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHATIC LEUKEMIA; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; OVARY CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SOLID TUMOR; STOMACH CANCER; SURVIVAL;

EID: 78650515906     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.10.013     Document Type: Article

References (252)

1. J.N. Timmer-Bonte, T.M. de Boo, and H.J. Smit Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study J Clin Oncol 23 2005 7974 7984
2. G.H. Lyman, D.C. Dale, J. Friedberg, J. Crawford, and R.I. Fisher Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study J Clin Oncol 22 2004 4302 4311
3. G.H. Lyman, V.A. Morrison, and D.C. Dale Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy Leuk Lymphoma 44 2003 2069 2076
4. G.H. Lyman, and D.J. Delgado Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma Cancer 98 2003 2402 2409
5. C.L. Vogel, M.Z. Wojtukiewicz, and R.R. Carroll First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study J Clin Oncol 23 2005 1178 1184
6. D. Wolff, J. Crawford, D. Dale, M. Poniewierski, and G. Lyman Risk of neutropenic complications based on a prospective nationwide registry of cancer patients initiating systematic chemotherapy Proc Am Soc Clin Oncol 23 2004 547 [abstract 6125]
7. D. Wolff, E. Culakova, and M. Poniewierski J Support Oncol 3 2005 2425
8. J. Crawford, D.C. Dale, and N.M. Kuderer Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice J Natl Compr Canc Netw 6 2008 109 118
9. W.T. Hughes, D. Armstrong, and G.P. Bodey 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer Clin Infect Dis 34 2002 730 751
10. D. Cameron Management of chemotherapy-associated febrile neutropenia Br J Cancer 101 Suppl. 1 2009 S18 S22
11. G. Padilla, and M.E. Ropka Quality of life and chemotherapy-induced neutropenia Cancer Nurs 28 2005 167 171
12. L.I. Wagner, J.L. Beaumont, and B. Ding Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the Functional Assessment of Cancer Therapy-Neutropenia (FACT-N) Support Care Cancer 16 2008 47 56
13. D. Krell, and A.L. Jones Impact of effective prevention and management of febrile neutropenia Br J Cancer 101 Suppl. 1 2009 S23 S26
14. J. Crawford Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia Semin Oncol 30 2003 24 30
15. M.D. Green, H. Koelbl, and J. Baselga A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Ann Oncol 14 2003 29 35
16. F.A. Holmes, S.E. Jones, and J. O'Shaughnessy Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer Ann Oncol 13 2002 903 909
17. F.A. Holmes, J.A. O'Shaughnessy, and S. Vukelja Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer J Clin Oncol 20 2002 727 731
18. C. Gisselbrecht, C. Haioun, and E. Lepage Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte Leuk Lymphoma 25 1997 289 300
19. M.S. Aapro, D.A. Cameron, and R. Pettengell EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours Eur J Cancer 42 2006 2433 2453
20. EMEA. Committee for medicinal products for human use summary of positive opinion for Hexal. [last accessed: 23rd April 2010]; 2008.
21. EMEA. Committee for medicinal products for human use summary of positive opinion for Zarzio. [last accessed: 23rd April 2010]; 2008.
22. EMEA. Committee for medicinal products for human use summary of positive opinion for tevagrastim. [last accessed: 23rd April 2010]; 2008.
23. EMEA. Committee for medicinal products for human use summary of positive opinion for filgrastim ratiopharm. [last accessed: 23rd April 2010]; 2008.
24. EMEA. Committee for medicinal products for human use summary of positive opinion for ratiograstim. [last accessed: 23rd April 2010]; 2008.
25. EMEA. Committee for medicinal products for human use summary of positive opinion for biograstim. [last accessed: 23rd April 2010]; 2008.
26. J. Crawford, C. Caserta, and F. Roila Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications Ann Oncol 21 Suppl. 5 2010 v248 v251
27. Chauhan R, Morgan S, Potter V. Guidelines for the management of febrile neutropenia in oncology patients. [last accessed: 23rd April 2010]; 2009.
28. D.R. Budman, D.A. Berry, and C.T. Cirrincione Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B J Natl Cancer Inst 90 1998 1205 1211
29. L.W. Kwak, J. Halpern, R.A. Olshen, and S.J. Horning Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis J Clin Oncol 8 1990 963 977
30. G. Bonadonna, P. Valagussa, A. Moliterni, M. Zambetti, and C. Brambilla Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up N Engl J Med 332 1995 901 906
31. E. Lepage, C. Gisselbrecht, and C. Haioun Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte) Ann Oncol 4 1993 651 656
32. J. Chang Chemotherapy dose reduction and delay in clinical practice. Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer Eur J Cancer 36 Suppl. 1 2000 S11 S14
33. C. Mayers, T. Panzarella, and I.F. Tannock Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma Cancer 91 2001 2246 2257
34. W.C. Wood, D.R. Budman, and A.H. Korzun Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma N Engl J Med 330 1994 1253 1259
35. S. Khan, A. Dhadda, D. Fyfe, and S. Sundar Impact of neutropenia on delivering planned chemotherapy for solid tumours Eur J Cancer Care (Engl) 17 2008 19 25
36. W.M. Hryniuk The importance of dose intensity in the outcome of chemotherapy Important Adv Oncol 1988 121 141
37. R. Pettengell, M. Schwenkglenks, and R. Leonard Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study Support Care Cancer 16 2008 1299 1309
38. A. Bosly, D. Bron, and A. Van Hoof Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP Ann Hematol 87 2008 277 283
39. I. Chirivella, B. Bermejo, and A. Insa Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients Breast Cancer Res Treat 114 2009 479 484
40. D. Radosavljevic, I. Golubicic, D. Gavrilovic, I. Kezic, and S. Jelic Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer? J BUON 14 2009 203 209
41. G.A. Sarosy, M.M. Hussain, and M.V. Seiden Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer Cancer 116 2010 476 484
42. H. Ozer, J.O. Armitage, and C.L. Bennett 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel J Clin Oncol 18 2000 3558 3585
43. National Comprehensive Cancer Network. Myeloid growth factors. [last accessed: Feb 2009].
44. G.H. Lyman, C.H. Lyman, and O. Agboola Risk models for predicting chemotherapy-induced neutropenia Oncologist 10 2005 427 437
45. J. Crawford, D.C. Dale, and G.H. Lyman Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management Cancer 100 2004 228 237
46. J. Crawford, J.A. Glaspy, and R.G. Stoller Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia Support Cancer Ther 3 2005 36 46
47. J. Baker, J. Ajani, and F. Scotte Docetaxel-related side effects and their management Eur J Oncol Nurs 13 2009 49 59
48. L. Meza, J. Baselga, F.A. Holmes, B. Liang, J. Breddy for the Pegfilgrastim Study Group Incidence of febrile neutropenia (FN) is directly related to duration of severe neutropenia (DSN) after myelosuppressive chemotherapy Proc Am Soc Clin Oncol 21 2002 225b [abstract 2840]
49. J. Klastersky, M. Paesmans, and E.B. Rubenstein The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients J Clin Oncol 18 2000 3038 3051
50. L. de Souza Viana, J.C. Serufo, M.O. da Costa Rocha, R.N. Costa, and R.C. Duarte Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients Support Care Cancer 16 2008 841 846
51. Klastersky J, Awada A, Paesmans M, Aoun M. Febrile neutropenia: a critical review of the initial management. Crit Rev Oncol Hematol 2010 [Epub ahead of print].
52. N.M. Kuderer, D.C. Dale, J. Crawford, L.E. Cosler, and G.H. Lyman Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients Cancer 106 2006 2258 2266
53. D.M. Courtney, A.Z. Aldeen, and S.M. Gorman Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care Oncologist 12 2007 1019 1026
54. A. Lal, Y. Bhurgri, and N. Rizvi Factors influencing in-hospital length of stay and mortality in cancer patients suffering from febrile neutropenia Asian Pac J Cancer Prev 9 2008 303 308
55. M. Cullen, N. Steven, and L. Billingham Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas N Engl J Med 353 2005 988 998
56. G. Bucaneve, A. Micozzi, and F. Menichetti Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia N Engl J Med 353 2005 977 987
57. A. Gafter-Gvili, A. Fraser, M. Paul, and L. Leibovici Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients Ann Intern Med 142 2005 979 995
58. Herbst C, Naumann F, Kruse EB, et al. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. Cochrane Database Syst Rev 2009:CD007107.
59. M.D. van de Wetering, M.A. de Witte, and L.C. Kremer Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials Eur J Cancer 41 2005 1372 1382
60. G. von Minckwitz, S. Kummel, and A. du Bois Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/ cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study Ann Oncol 19 2008 292 298
61. M. Cullen, and S. Baijal Prevention of febrile neutropenia: use of prophylactic antibiotics Br J Cancer 101 Suppl. 1 2009 S11 S14
62. M. Bonadio, G. Morelli, and S. Mori Fluoroquinolone resistance in hematopoietic stem cell transplant recipients with infectious complications Biomed Pharmacother 59 2005 511 516
63. A. Younes, L. Fayad, and J. Romaguera Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma Eur J Cancer 42 2006 2976 2981
64. S.A. Gregory, and L. Trumper Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes? Ann Oncol 16 2005 1413 1424
65. M. Pfreundschuh, L. Trumper, and M. Kloess Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL Blood 104 2004 626 633 (Pubitemid 38970553)
66. M. Pfreundschuh, L. Trumper, and M. Kloess Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL Blood 104 2004 634 641 (Pubitemid 38970554)
67. N. Thatcher, D.J. Girling, and P. Hopwood Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party J Clin Oncol 18 2000 395 404
68. G. Fountzilas, U. Dafni, and H. Gogas Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00 Ann Oncol 19 2008 853 860 (Pubitemid 351649185)
69. S. Kummel, J. Krocker, and A. Kohls Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer Br J Cancer 94 2006 1237 1244
70. L.F. Verdonck, A. Notenboom, and D.D. de Jong Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) Blood 109 2007 2759 2766
71. D. Hershman, A.I. Neugut, and J.S. Jacobson Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy J Natl Cancer Inst 99 2007 196 205
72. I.P. Touw, and M. Bontenbal Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy? J Natl Cancer Inst 99 2007 183 186
73. G. Lyman, D. Dale, and D.A. Wolff Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review J Clin Oncol 28 2010 2914 2924
74. T.J. Smith, J. Khatcheressian, and G.H. Lyman 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 2006 3187 3205
75. C.T. Kouroukis, S. Chia, and S. Verma Canadian supportive care recommendations for the management of neutropenia in patients with cancer Curr Oncol 15 2008 9 23
76. R. Greil, and O. Psenak Hematopoietic growth factors: ESMO recommendations for the application Ann Oncol 18 Suppl. 2 2007 ii89 ii91
77. Gohil S, Sharma A, Harper-Wynne C. Comparison of rates of febrile neutropenia using FEC100/Docetaxel100 chemotherapy in breast cancer patients with and without primary GCSF prophylaxis. In: National Cancer Research Institute Cancer Conference, 4-7 October, Birmingham, UK, 2009 [abstract B75].
78. Scaife J, Matthews R, Jenkins P. Febrile neutropenia in patients receiving TAC chemotherapy for breast cancer. In: National Cancer Research Institute Cancer Conference, 5-8 October, Birmingham, UK; 2008 [abstract BOA14].
79. Ali Z, O'Reilly S, Zahoor T, Schofield P, Malik Z. Experience of febrile neutropenia and secondary G-CSF prophylaxis during FEC-D chemotherapy in Merseyside and Cheshire Cancer Network. In: National Cancer Research Institute Cancer Conference, 5-8 October, Birmingham, UK; 2008 [abstract B67].
80. Head J, Archer C, Harper-Wynne C, et al. Rates of neutropaenic sepsis with the use of adjuvant FEC100-Docetaxel (FEC100-T) chemotherapy in high-risk node-positive patients with early breast cancer; a UK perspective. In: National Cancer Research Institute Cancer Conference, 5-8 October, Birmingham, UK; 2008 [abstract B64].
81. F. Ricci, A. Tedeschi, E. Morra, and M. Montillo Fludarabine in the treatment of chronic lymphocytic leukemia: a review Ther Clin Risk Manag 5 2009 187 207
82. I.W. Flinn, D.S. Neuberg, and M.R. Grever Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997 J Clin Oncol 25 2007 793 798
83. C.S. Tam, S. O'Brien, and W. Wierda Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia Blood 112 2008 975 980
84. Hallek M, Fingerle-Rowson G, Fink A-M, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group. Blood (ASH Annual Meeting Abstracts) 2009;114 [abstract 535].
85. M.J. Millward, M.J. Boyer, and M. Lehnert Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients Ann Oncol 14 2003 449 454
86. L. Gianni, E. Munzone, and G. Capri Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study J Clin Oncol 13 1995 2688 2699
87. S.D. Fossa, S.B. Kaye, and G.M. Mead Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom J Clin Oncol 16 1998 716 724
88. V.C. Tjan-Heijnen, P.E. Postmus, and A. Ardizzoni Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study Ann Oncol 12 2001 1359 1368
89. A. Ravaud, C. Chevreau, and L. Cany Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial J Clin Oncol 16 1998 2930 2936
90. E. Vellenga, C.A. Uyl-de Groot, and R. de Wit Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia J Clin Oncol 14 1996 619 627
91. Brooks J, Chrischilles E, Chen-Hardee, SS. The implications of treatment effect heterogeneity on using cost-effectiveness analysis for optimal prescribing: the case of primary G-CSF for non-Hodgkin's lymphoma patients. in preparation.
92. F. Hilpert, A. du Bois, and E.R. Greimel Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged > or=70 years with advanced ovarian cancer - a study by the AGO OVAR Germany Ann Oncol 18 2007 282 287
93. R. Pettengell, A. Bosly, and T.D. Szucs Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study Br J Haematol 144 2009 677 685
94. S.R. Teegala, X. Zhou, and A. Huen Risk factors for neutropenic fever in lymphoma patients receiving chemotherapy J Clin Oncol 2007 25 [abstract 19616]
95. G. Dranitsaris, D. Rayson, and M. Vincent Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model Am J Clin Oncol 31 2008 369 374
96. M. Shayne, E. Culakova, and M.S. Poniewierski Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy Cancer 110 2007 1611 1620
97. M. Moreau, J. Klastersky, and A. Schwarzbold A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies Ann Oncol 20 2009 513 519
98. P. Jenkins, and S. Freeman Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer Ann Oncol 20 2009 34 40
99. Schwenkglenks M, Pettengell R, Jackisch C, et al. Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study. Ann Oncol 2010 [Epub ahead of print].
100. D.C. Dale, A.A. Bolyard, and B.G. Schwinzer The Severe Chronic Neutropenia International Registry: 10-Year follow-up report Support Cancer Ther 3 2006 220 231
101. G.H. Lyman, E.D. Crawford, A. Dale, D. Wolff, E. Culakova for the ANC Study Group Predicting the risk of neutropenic complications and reduced dose intensity in patients with early-stage breast cancer (ESBC): Results from a prospective nationwide registry Proc Am Soc Clin Oncol 24 2004 70 [abstract 776]
102. J. Alexandre, E. Rey, and V. Girre Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study Ann Oncol 18 2007 168 172
103. L.J. Worth, M.J. Dooley, and J.F. Seymour An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital Br J Cancer 92 2005 867 872
104. L. Repetto, L. Biganzoli, and C.H. Koehne EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer Eur J Cancer 39 2003 2264 2272
105. R. Pirker, J.R. Pereira, and A. Szczesna Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 2009 1525 1531
106. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
107. M. Reck, J. von Pawel, and P. Zatloukal Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil J Clin Oncol 27 2009 1227 1234
108. D. Miles, A. Chan, and G. Romieu Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO J Clin Oncol 26 2008 15S [abstract LBA1011]
109. E.A. Perez, L. Geeraerts, and V.J. Suman A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer Ann Oncol 13 2002 1225 1235
110. G. von Minckwitz, G. Raab, and A. Caputo Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group J Clin Oncol 23 2005 2676 2685
111. E. Alba, M. Martin, and M. Ramos Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study J Clin Oncol 22 2004 2587 2593
112. J.M. Nabholtz, C. Falkson, and D. Campos Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial J Clin Oncol 21 2003 968 975
113. L. Biganzoli, T. Cufer, and P. Bruning Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial J Clin Oncol 20 2002 3114 3121
114. M. Martin, A. Ruiz, and M. Munoz Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial Lancet Oncol 8 2007 219 225
115. B. Chevallier, P. Chollet, and Y. Merrouche Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer J Clin Oncol 13 1995 1564 1571
116. M.L. Citron, D.A. Berry, and C. Cirrincione Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 2003 1431 1439
117. P. Therasse, L. Mauriac, and M. Welnicka-Jaskiewicz Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study J Clin Oncol 21 2003 843 850
118. B. Norris, K.I. Pritchard, and K. James Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8 J Clin Oncol 18 2000 2385 2394
119. J. O'Shaughnessy, D. Miles, and S. Vukelja Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 2002 2812 2823
120. P. Fumoleau, F. Chauvin, and M. Namer Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes J Clin Oncol 19 2001 612 620
121. G. Romieu, M. Clemens, and R. Mahlberg Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial Crit Rev Oncol Hematol 64 2007 64 72
122. R.L. Jones, G. Walsh, and S. Ashley A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer Br J Cancer 100 2009 305 310
123. H. Stoger, H. Samonigg, and M. Krainer Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor Eur J Cancer 34 1998 482 488
124. M.N. Levine, V.H. Bramwell, and K.I. Pritchard Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 16 1998 2651 2658
125. I.F. Tannock, N.F. Boyd, and G. DeBoer A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer J Clin Oncol 6 1988 1377 1387
126. I.G. Ron, N. Wigler, and R. Borovik CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter study Am J Clin Oncol 24 2001 323 327
127. J. Jassem, T. Pienkowski, and A. Pluzanska Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial J Clin Oncol 19 2001 1707 1715
128. P. Papaldo, M. Lopez, and P. Marolla Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide J Clin Oncol 23 2005 6908 6918
129. A. Ardizzoni, C. Manegold, and C. Debruyne European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer Clin Cancer Res 9 2003 143 150
130. V. Trillet-Lenoir, J. Green, and C. Manegold Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy Eur J Cancer 29A 1993 319 324
131. J. von Pawel, J.H. Schiller, and F.A. Shepherd Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer J Clin Oncol 17 1999 658 667
132. P. Lorigan, P.J. Woll, and M.E. O'Brien Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer J Natl Cancer Inst 97 2005 666 674
133. P.J. Woll, J. Hodgetts, and L. Lomax Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized
134. M. Masutani, Y. Ochi, and A. Kadota Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors? Oncol Rep 7 2000 305 310
135. S.C. White, P. Lorigan, and M.R. Middleton Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma Cancer 92 2001 601 608
136. A. Ardizzoni, V.C. Tjan-Heijnen, and P.E. Postmus Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923 J Clin Oncol 20 2002 3947 3955
137. Q.T. Le, J. Moon, and M. Redman Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222 J Clin Oncol 27 2009 3014 3019
138. K. Furuse, M. Fukuoka, and Y. Nishiwaki Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group J Clin Oncol 16 1998 2126 2132
139. M. Masutani, I. Tsujino, and T. Fujie Moderate dose-intensive chemotherapy for patients with non-small cell lung cancer: randomized trial, can it improve survival of patients with good performance status? Oncol Rep 6 1999 1045 1050
140. M.J. Edelman, K. Chansky, and L.E. Gaspar Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/ carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713 J Clin Oncol 22 2004 127 132
141. A. Font, A.J. Moyano, and J.M. Puerto Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group Cancer 85 1999 855 863
142. E. Baldini, A. Ardizzoni, and T. Prochilo Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC) Cancer Chemother Pharmacol 49 Suppl. 1 2002 S25 S28
143. J.H. Schiller, D. Harrington, and C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
144. F. Fossella, J.R. Pereira, and J. von Pawel Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group J Clin Oncol 21 2003 3016 3024
145. A.J. Wozniak, J.J. Crowley, and S.P. Balcerzak Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study J Clin Oncol 16 1998 2459 2465
146. K. Kelly, J. Crowley, and P.A. Bunn Jr. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 19 2001 3210 3218
147. G.P. Stathopoulos, S.K. Rigatos, and M.A. Dimopoulos Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer Ann Oncol 14 2003 388 394
148. P. Kosmidis, N. Mylonakis, and A. Dimopoulos Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Preliminary results. Hellenic Cooperative Oncology Group Semin Oncol 27 2000 3 8
149. G.V. Scagliotti, F. De Marinis, and M. Rinaldi Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol 20 2002 4285 4291
150. F. Cardenal, M.P. Lopez-Cabrerizo, and A. Anton Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 17 1999 12 18
151. W.S. Velasquez, P. McLaughlin, and S. Tucker ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study J Clin Oncol 12 1994 1169 1176
152. P.W. Johnson, J.W. Sweetenham, and P. McCallum E-SHAP: inadequate treatment for poor-prognosis recurrent lymphoma Ann Oncol 4 1993 63 67
153. M.A. Ozturk, I. Barista, and M.K. Altundag Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin Chemotherapy 48 2002 252 258
154. A. Martin, E. Conde, and M. Arnan R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study Haematologica 93 2008 1829 1836
155. E. Osby, H. Hagberg, and S. Kvaloy CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial Blood 101 2003 3840 3848
156. R. Pettengell, H. Gurney, and J.A. Radford Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial Blood 80 1992 1430 1436
157. M.S. Hertzberg, C. Crombie, and W. Benson Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease Ann Oncol 14 Suppl. 1 2003 i11 i16
158. Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. Ann Oncol 2006;17(Suppl. 4):iv25-30.
159. P.G. Gobbi, A. Levis, and T. Chisesi ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi J Clin Oncol 23 2005 9198 9207
160. D. Catovsky, S. Richards, and E. Matutes Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial Lancet 370 2007 230 239
161. G. Martinelli, P.F. Ferrucci, and W. Mingrone ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphoma Leuk Lymphoma 44 2003 801 806
162. M.A. Dimopoulos, G. Fountzilas, and E. Papageorgiou Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group Leuk Lymphoma 43 2002 111 114
163. W.H. Wilson, K. Dunleavy, and S. Pittaluga Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers J Clin Oncol 26 2008 2717 2724
164. J. Garcia-Suarez, H. Banas, and I. Arribas Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study Br J Haematol 136 2007 276 285
165. C.H. Geisler, A. Kolstad, and A. Laurell Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group Blood 112 2008 2687 2693
166. M. Ng, J. Waters, and D. Cunningham Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma Br J Cancer 92 2005 1352 1357
167. A. Lopez, A. Gutierrez, and A. Palacios GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study Eur J Haematol 80 2008 127 132
168. V. Diehl, J. Franklin, and M. Pfreundschuh Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease N Engl J Med 348 2003 2386 2395
169. M. Federico, S. Luminari, and E. Iannitto ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial J Clin Oncol 27 2009 805 811
170. V. Ballova, J.U. Ruffer, and H. Haverkamp A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly) Ann Oncol 16 2005 124 131
171. F. Silvestri, R. Fanin, and M. Velisig The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease Tumori 80 1994 453 458
172. A. Santoro, M. Magagnoli, and M. Spina Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma Haematologica 92 2007 35 41
173. C.F. Verschraegen, T. Sittisomwong, and A.P. Kudelka Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma J Clin Oncol 18 2000 2733 2739
174. G.A. Omura, M.F. Brady, and K.Y. Look Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study J Clin Oncol 21 2003 2843 2848
175. G.J. Creemers, G. Bolis, and M. Gore Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study J Clin Oncol 14 1996 3056 3061
176. A.E. Guppy, A.E. Nelstrop, and T. Foster A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer Br J Cancer 90 2004 810 814
177. A. du Bois, H.J. Luck, and W. Meier A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 2003 1320 1329
178. A.N. Gordon, L. Asmar, and M.J. Messing Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer Gynecol Oncol 94 2004 533 539
179. C.A. Papadimitriou, G. Fountzilas, and G. Aravantinos Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study Gynecol Oncol 92 2004 152 159 (Pubitemid 38147384)
180. D.J. Vaughn, S.B. Malkowicz, and B. Zoltick Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen J Clin Oncol 16 1998 255 260
181. C.N. Sternberg, P.H. de Mulder, and J.H. Schornagel Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924 J Clin Oncol 19 2001 2638 2646
182. K.D. Miller, P.J. Loehrer, R. Gonin, and L.H. Einhorn Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma J Clin Oncol 15 1997 1427 1431
183. R.J. Motzer, J. Sheinfeld, and M. Mazumdar Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors J Clin Oncol 13 1995 2700 2704
184. E. Van Cutsem, P.M. Hoff, and P. Harper Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials Br J Cancer 90 2004 1190 1197
185. J.Y. Douillard, D. Cunningham, and A.D. Roth Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 2000 1041 1047
186. P. Leonard, M.T. Seymour, R. James, D. Hochhauser, and J.A. Ledermann Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer Br J Cancer 87 2002 1216 1220
187. M. Mabro, C. Louvet, and T. Andre Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer Am J Clin Oncol 26 2003 254 258
188. F. Maindrault-Goebel, A. de Gramont, and C. Louvet High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7) Eur J Cancer 37 2001 1000 1005
189. H. Sorbye, B. Glimelius, and A. Berglund Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer J Clin Oncol 22 2004 31 38
190. L.B. Saltz, J.V. Cox, and C. Blanke Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 2000 905 914
191. C.S. Fuchs, M.R. Moore, and G. Harker Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer J Clin Oncol 21 2003 807 814
192. N.E. Schoemaker, I.E. Kuppens, and V. Moiseyenko A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer Br J Cancer 91 2004 1434 1441
193. O. Bouche, J.L. Raoul, and F. Bonnetain Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study - FFCD 9803 J Clin Oncol 22 2004 4319 4328
194. E. Van Cutsem, V.M. Moiseyenko, and S. Tjulandin Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 2006 4991 4997
195. A.D. Roth, N. Fazio, and R. Stupp Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research J Clin Oncol 25 2007 3217 3223
196. S.R. Park, J.H. Chun, and M.S. Yu Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma Br J Cancer 94 2006 1402 1406
197. C. Louvet, T. Andre, and J.M. Tigaud Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients J Clin Oncol 20 2002 4543 4548
198. D.M. Shin, F.R. Khuri, and B.S. Glisson Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma Cancer 91 2001 1316 1323
199. B.N. Bui, B. Chevallier, and C. Chevreau Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity J Clin Oncol 13 1995 2629 2636
200. P.G. Rose, J.A. Blessing, D.M. Gershenson, and R. McGehee Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study J Clin Oncol 17 1999 2676 2680
201. G.F. Fleming, V.L. Brunetto, and D. Cella Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study J Clin Oncol 22 2004 2159 2166 (Pubitemid 41095150)
202. Y. Pointreau, P. Garaud, and S. Chapet Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation J Natl Cancer Inst 101 2009 498 506
203. D. Cunningham, N. Starling, and S. Rao Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 2008 36 46
204. A.M. Capotorto, L. Pavesi, and P. Pedrazzoli Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin- cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma J Chemother 15 2003 184 191
205. G. Frasci, P. Comella, and I. Carreca Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study Oncology 68 2005 223 229
206. D.F. Heigener, C. Manegold, and E. Jager Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage Am J Clin Oncol 32 2009 61 64
207. A.A. Miller, X.F. Wang, and L. Gu Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303) J Thorac Oncol 3 2008 1159 1165
208. J.N. Timmer-Bonte, C.J. Punt, and H.F. vd Heijden Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer Lung Cancer 60 2008 222 230
209. E. Brusamolino, C. Rusconi, and L. Montalbetti Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity Haematologica 91 2006 496 502
210. U.J. Mey, A. Maier, and I.G. Schmidt-Wolf Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma Support Care Cancer 15 2007 877 884
211. P. Piedbois, D. Serin, and F. Priou Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study Ann Oncol 18 2007 52 57
212. D. Cunningham, P. Smith, and P. Mouncey A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma J Clin Oncol 2009 27 [abstract 8506]
213. R. Delarue, H. Tilly, and G. Salles R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-Cell lymphoma: results of the interim analysis of the LNH03-6B GELA study Blood (ASH Annual Meeting Abstracts) 2009 114 [abstract 406]
214. B.B. Yang, A. Kido, and A. Shibata Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy Pharmacotherapy 27 2007 1387 1393
215. H.B. Niell, J.E. Herndon 2nd, and A.A. Miller Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732 J Clin Oncol 23 2005 3752 3759
216. I. Ray-Coquard, D. Paraiso, and J.P. Guastalla Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group Br J Cancer 97 2007 1200 1205
217. Lyman G, Kuderer NM, Crawford J, et al. Impact of pegfilgrastim on early all-cause mortality in patients receiving cancer chemotherapy. J Clin Oncol 2008;26. (abstract 6552).
218. G.H. Lyman, N.M. Kuderer, and B. Djulbegovic Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis Am J Med 112 2002 406 411
219. U. Gatzemeier, J.P. Kleisbauer, and P. Drings Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study Am J Clin Oncol 23 2000 393 400
220. A. Hackshaw, J. Sweetenham, and A. Knight Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma? Br J Cancer 90 2004 1302 1305
221. M. Hidalgo, C. Mendiola, and J.M. Lopez-Vega A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain Cancer 83 1998 719 725
222. Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma (Review). Cochrane Database Syst Rev 2008 8;(4):CD003189. doi:10.1002/14651858.CD003189.pub4. 2008.
223. N.M. Kuderer, D.C. Dale, J. Crawford, and G.H. Lyman Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review J Clin Oncol 25 2007 3158 3167
224. A.R. Clamp, W.D. Ryder, S. Bhattacharya, R. Pettengell, and J.A. Radford Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma Br J Cancer 99 2008 253 258
225. Lang K, O'Hea A-M, Eagleton H. Prophylaxis of neutropenic complications during CHOP-R chemotherapy using GCSF: a 3 year case-control study. In: National Cancer Research Institute Cancer Conference, 4-7 October, Birmingham, UK; 2009 [abstract C71].
226. J. Crawford, H. Ozer, and R. Stoller Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer N Engl J Med 325 1991 164 170
227. Y. Terada, H. Nakamae, and R. Moriguchi The impact of relative dose intensity of rituximab-CHOP on survival in Diffuse Large B-Cell Lymphoma patients Blood (ASH Annual Meeting Abstracts) 2008 112 [abstract 4931]
228. T. Hirakawa, H. Yamaguchi, and S. Gomi Importance of relative dose intensity for survival in Diffuse Large B-Cell Lymphoma Patients treated with CHOP-Like regimen Blood (ASH Annual Meeting Abstracts) 2008 112 [abstract 3605]
229. L. Balducci, H. Al-Halawani, and V. Charu Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim Oncologist 12 2007 1416 1424
230. G. von Minckwitz, M. Schwenkglenks, and T. Skacel Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management: Results from an integrated analysis Eur J Cancer 45 2009 608 617
231. M. Martin, A. Lluch, and M.A. Segui Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen Ann Oncol 17 2006 1205 1212
232. Campbell C, Bramwell V, Charette M, Oliver T, and the Systemic Treatment Disease Site Group. The role of colony-stimulating factor (CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer practice guideline report #12-2 (version 2.2003). [last accessed: Feb 2009].
233. O.A. Clark, G.H. Lyman, A.A. Castro, L.G. Clark, and B. Djulbegovic Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials J Clin Oncol 23 2005 4198 4214
234. R. Garcia-Carbonero, J.I. Mayordomo, and M.V. Tornamira Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial J Natl Cancer Inst 93 2001 31 38
235. J.M. Vose, M. Crump, and H. Lazarus Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma J Clin Oncol 21 2003 514 519
236. A. Grigg, P. Solal-Celigny, and P. Hoskin Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma Leuk Lymphoma 44 2003 1503 1508
237. A. Engert, A. del Giglio, and P. Bias Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma Onkologie 32 2009 599 604
238. A. Engert, L. Griskevicius, Y. Zyuzgin, H. Lubenau, and A. del Giglio XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy Leuk Lymphoma 50 2009 374 379
239. A. del Giglio, A. Eniu, D. Ganea-Motan, E. Topuzov, and H. Lubenau XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy BMC Cancer 8 2008 332
240. H. Lubenau, A. Sveikata, and G. Gumbrevicius Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers Int J Clin Pharmacol Ther 47 2009 275 282
241. U. Gatzemeier, T. Ciuleanu, and M. Dediu XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy J Thorac Oncol 4 2009 736 740
242. H. Lubenau, P. Bias, A.K. Maly, K.E. Siegler, and K. Mehltretter Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial BioDrugs 23 2009 43 51
243. P. Gascon, U. Fuhr, and F. Sorgel Development of a new G-CSF product based on biosimilarity assessment Ann Oncol 21 2010 1419 1429
244. EMEA.Questions and Answers on biosimilar medicines (similar biological medicinal products). [last accessed: 8th March 2010].
245. L. Pinto, Z. Liu, and Q. Doan Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials Curr Med Res Opin 23 2007 2283 2295
246. J.L. Misset, V. Dieras, and G. Gruia Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer Ann Oncol 10 1999 553 560
247. D. Almenar, J. Mayans, and O. Juan Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain - results of the LEARN Study Eur J Cancer Care (Engl) 18 2009 280 286
248. V.A. Morrison, M. Wong, and D. Hershman Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices J Manag Care Pharm 13 2007 337 348
249. C. Haioun, U. Jaeger, and P. Lugtenburg Risk of febrile neutropenia and use of G-CSF primary prophylaxis in non-Hodgkin's Lymphoma patients receiving R-CHOP-21 Haematologica 93 s1 2008 105 [abstract 0258]
250. A. Engert, H. Bredenfeld, and H. Dohner Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study Haematologica 91 2006 546 549
251. M. Akutsu, S. Tsunoda, and T. Izumi Long-term results of dose-intensive chemotherapy with G-CSF support (TCC-NHL-91) for advanced intermediate-grade non-Hodgkin's lymphoma: a review of 59 consecutive cases treated at a single institute Oncol Res 17 2008 137 149
252. EMA. Committee for medicinal products for human use summary of positive opinion for nivestim. . [last accessed: 18 October 2010]; 2010.